논문 상세보기

Coronavirus disease 2019 as a systemic disease: a review KCI 등재

  • 언어ENG
  • URLhttps://db.koreascholar.com/Article/Detail/404391
구독 기관 인증 시 무료 이용이 가능합니다. 4,000원
충북대학교 동물의학연구소 (Research Institute of Veterinary Medicine, Chungbuk National University)
초록

Since a cluster of pneumonia cases of unknown etiology was first reported in China in December 2019, the number of confirmed cases with coronavirus disease 2019 (COVID-19) (caused by severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) worldwide has been increasing, and nearly two million patients are expected to have died by February 2021. Globally, COVID-19 is being considered a primary pulmonary disease, but it is more than a lung infection. This is because patients infected with SARS-CoV-2 present with a variety of clinical signs and symptoms involving many organs, ranging from fever, inflammation, myocardial injury, shock, and the development of coronary artery aneurysm. SARS-CoV-2 shows unique characteristics in its transmission, mortality, and stability in different environmental conditions. During COVID-19 pandemic, about 10 drugs have been clinically tried with none proven to be effective. With no prospect for effective drugs in the near future, there are currently possibilities of success with vaccines and convalescent plasma. Along with the prospect of vaccines and other therapeutic drugs, special precautions (isolation, testing, treating, and tracing) are strictly recommended until we return to normal situations. In this review we comprehensively analyzed the clinical presentations, characteristics, and outcomes of patients with COVID-19, and tried to assess the clinical effects of some drugs as part of the ongoing efforts to understand COVID-19 pandemic.

목차
Introduction
Systemic Effects of COVID-19
    Pulmonary system
    Cardiovascular system
    Genitourinary system
    Digestive system
    Neurologic system
    Intensive care unit
Special Occasions with COVID-19
    Pregnant women
    Neonates
    BCG vaccination and SARS-CoV-2
    Proton pump inhibitor (PPI) and COVID-19
    Cancer
    Obesity
Diagnosis
Treatment
    Chloroquine
    Hydroxychloroquine
    Remdesivir
    Convalescent plasma
    Lopinavir-ritonavir
    Dexamethasone
Prevention/vaccine
Discussion
References
저자
  • Hoon Kang(Department of Anesthesiology and Pain Medicine, College of Medicine, Chungbuk National University) Corresponding author
  • Donggeun Lee(Department of Plastic Surgery, Chungbuk National University Hospital)
  • Jinsol Lee(Department of Anesthesiology and Pain Medicine, Chungbuk National University Hospital)